These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34328006)

  • 1. Complete resolution of chylothorax with ibrutinib in chronic lymphocytic leukemia: a case report.
    Cheng L; Huang M; Wei J; Xu H; Zhou M; Jiang L
    Ann Palliat Med; 2022 May; 11(5):1833-1837. PubMed ID: 34328006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete resolution of chylopericardium after chemotherapy for chronic lymphocytic leukemia.
    Morris AL; Colbourne T; Kirkpatrick I; Banerji V
    Curr Oncol; 2019 Oct; 26(5):e696-e699. PubMed ID: 31708663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non hemorrhagic pericardial effusion from ibrutinib İn a patient without comorbidities.
    Aslan Candır B; Yiğenoğlu TN; Kızıl Çakar M; Dal MS; Altuntaş F
    J Oncol Pharm Pract; 2022 Jun; 28(4):972-974. PubMed ID: 35006020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation.
    Yang S; Zhu R; Li N; Feng Y; Zuo R; Gale RP; Huang X
    Acta Haematol; 2022; 145(1):54-62. PubMed ID: 34569486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chylous effusion complicating chronic lymphocytic leukemia.
    Ampil FL; Burton GV; Hardjasudarma M; Stogner SW
    Leuk Lymphoma; 1993 Aug; 10(6):507-10. PubMed ID: 8401188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Fludarabine for the Treatment of Indolent Lymphoma with Chylothorax.
    Wild A; Holasová J; Králiková E
    Klin Onkol; 2018; 31(4):301-304. PubMed ID: 30541315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chylothorax Associated with Chronic Lymphocytic Leukemia.
    Kohmoto O; Kawabe K; Ono H; Yanagimoto R; Arimoto J; Hatada A; Suruda T; Minakata Y
    Intern Med; 2016; 55(24):3641-3644. PubMed ID: 27980266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chylothorax in chronic lymphocytic leukemia patient.
    Doerr CH; Staats BA; Markovic SN
    Am J Hematol; 2002 Jul; 70(3):237-40. PubMed ID: 12111770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world Prescription Pattern, Discontinuation and Costs of Ibrutinib-Naïve Patients with Chronic Lymphocytic Leukemia: An Italian Healthcare Administrative Database Analysis.
    Ronconi G; Dondi L; Calabria S; Piccinni C; Pedrini A; Esposito I; Martini N
    Clin Drug Investig; 2021 Jul; 41(7):595-604. PubMed ID: 34032988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persisting right-sided chylothorax in a patient with chronic lymphocytic leukemia: a case report.
    Scholz GA; Sirbu H; Semrau S; Anders K; Mackensen A; Spriewald BM
    J Med Case Rep; 2011 Oct; 5():492. PubMed ID: 21968097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia.
    Huntington SF; de Nigris E; Puckett J; Kamal-Bahl S; Farooqui M; Ryland K; Sarpong E; Leng S; Yang X; Doshi JA
    Leuk Lymphoma; 2023 Dec; 64(14):2286-2295. PubMed ID: 37870435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cryoglobulinemic vasculitis with interruption of ibrutinib therapy for chronic lymphocytic leukemia (CLL).
    Wright N; Voshtina E; George G; Singavi A; Field J
    Int J Hematol; 2019 Dec; 110(6):751-755. PubMed ID: 31494832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
    Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
    Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
    Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor lysis syndrome in a chronic lymphocytic leukemia patient with pleural effusion after oral fludarabine and cyclophosphamide therapy.
    Nakazawa H; Nishina S; Mimura Y; Kawakami T; Senoo Y; Sakai K; Nakazawa K; Kitano K
    Int J Hematol; 2014 Jun; 99(6):782-5. PubMed ID: 24584911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Fraser G; Cramer P; Demirkan F; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Pavlovsky MA; Karlsson C; Hallek M; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Chanan-Khan A
    Leukemia; 2019 Apr; 33(4):969-980. PubMed ID: 30315239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
    Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA
    Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemorrhagic pleural effusion as a complication of chronic lymphocytic leukemia.
    Zeidman A; Yarmolovsky A; Djaldetti M; Mittelman M
    Haematologia (Budap); 1995; 26(3):173-5. PubMed ID: 7797147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALK-positive histiocytosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: a multitarget response under ibrutinib.
    Syrykh C; Ysebaert L; Péricart S; Evrard SM; Meggetto F; Kanoun S; Brousset P; Laurent C
    Virchows Arch; 2021 Apr; 478(4):779-783. PubMed ID: 33011863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
    Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
    Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.